The scientific goal of the Cancer Control (CC) Program is to foster population-based research that will lead to a reduction in cancer morbidity and mortality in South Carolina (SC) while providing scientific evidence and novel cancer control interventions that can be applied beyond the state's borders. The CC Program investigators have made substantive progress toward this goal primarily through focused research efforts in two major themes - generating novel insights and approaches to tobacco control and addressing cancer health disparities. Within these two themes, the CC Program members work collaboratively to conduct and link research that identifies behavioral risk factors predisposing individuals to cancer development and to translate these findings into cost effective, sustainable interventions to modify risk factors. Furthermore, the CC Program members are working with government and community leaders to disseminate these evidence based strategies to impact the cancer burden in SC. Currently, the CC Program consists of 23 members representing 11 departments from within the College of Medicine, College of Nursing and the College of Pharmacy with more than $4.6M in peer-reviewed extramural research funding ($1.6M from the NCI) and another $640K in program-supportive training and career development awards. In the past five years, program members produced 170 publications with 17% of these representing inter-programmatic and 29% intra-programmatic collaborations, and 57% from multi-institutional collaborations.
The Hollings Cancer Center's Cancer Control Program conducts population-based research focused on reducing cancer morbidity and mortality in South Carolina while providing scientific evidence and novel cancer control interventions that can be applied beyond the state's borders.
|Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46|
|Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6|
|Podbielska, Maria; Szulc, ZdzisÅ‚aw M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039|
|Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25|
|Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95|
|Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30|
|Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7|
|Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50|
|Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203|
|Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263|
Showing the most recent 10 out of 311 publications